PRT543

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Advanced Solid Tumors

Conditions

Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia

Trial Timeline

Feb 11, 2019 → Nov 16, 2022

NCT ID

NCT03886831

About PRT543

PRT543 is a phase 1 stage product being developed by Prelude Therapeutics for Relapsed/Refractory Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03886831. Target conditions include Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03886831	Phase 1	Completed	Feb 11, 2019	Nov 16, 2022	Relapsed/Refractory Advanced Solid Tumors

Competing Products

20 competing products in Relapsed/Refractory Advanced Solid Tumors

See all competitors

Product	Company	Stage	Hype Score
agenT-797	MiNK Therapeutics	Phase 1	25
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Eribulin mesylate	Eisai	Phase 2	52
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41
ISB 1342	Glenmark Pharmaceuticals	Phase 1	33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	77
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	52
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	33
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	33
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	41
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	33
AZD4573	AstraZeneca	Phase 2	52
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	23
Administration of AZD6738	AstraZeneca	Phase 1	33

Other Products from Prelude Therapeutics

PRT811Phase 1

PRT1419 + Azacitidine + VenetoclaxPhase 1

PRT1419Phase 1

PRT12396Phase 1

PRT3645Phase 1